Allergy Therapeutics (LON:AGY) Hits New 1-Year High – Here’s Why

Allergy Therapeutics plc (LON:AGY)’s stock price hit a new 52-week high on Wednesday . The stock traded as high as GBX 12.10 and last traded at GBX 12.10, with a volume of 469480 shares traded. The stock had previously closed at GBX 11.70.

Allergy Therapeutics Stock Performance

The firm’s 50 day simple moving average is GBX 11.24 and its 200 day simple moving average is GBX 9.59. The firm has a market capitalization of £743.11 million, a price-to-earnings ratio of -14.40, a PEG ratio of -30.70 and a beta of 1.40. The company has a debt-to-equity ratio of 835.48, a quick ratio of 1.48 and a current ratio of 1.63.

Allergy Therapeutics (LON:AGY) last issued its earnings results on Monday, February 16th. The company reported GBX (0.84) earnings per share (EPS) for the quarter. Allergy Therapeutics had a negative return on equity of 266.59% and a negative net margin of 72.86%. Sell-side analysts forecast that Allergy Therapeutics plc will post -2.56 earnings per share for the current fiscal year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.